Long-term results of GH therapy in GH-deficient children treated before 1 year of age

Huet, Frédéric; Jc, Carel; Nivelon, J L; Chaussain, J. L.

doi:10.1530/eje.0.1400029

Cited by 40 publications

(41 citation statements)

References 23 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, our 7-year prospective study on GHD infants treated with GH from less than two years of age has confirmed the conclusions of other recent prospective (11) and retrospective (12)(13)(14)(15) treatment of GHD in childhood. Moreover it has demonstrated that the influence of BW on growth response to GH therapy in GHD children persists over time, at least when treatment is begun from less than two years of age.…”

Section: Discussionsupporting

confidence: 88%

Birth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age of 2 years

Waśniewska

Arrigo²,

Cisternino

et al. 2000

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To investigate which pretreatment variables most significantly affect long-term growth response to GH therapy in children with apparently idiopathic GH deficiency (GHD) treated from a similar and very young age (less than 2 years), for the same period (7 years) and with the same therapeutic protocol. Design and methods: Twelve children with either isolated GHD or multiple pituitary hormone deficiency were treated with biosynthetic human GH (0.7 IU/kg per week) and were examined every 6 months. Height measurements were performed by Harpenden stadiometers. Bone age was evaluated every 12 months. Results: The onset of therapy was followed in all patients by an important height gain, which attained its zenith during the first year of treatment and became progressively less evident during the next 4 years. Cumulative height gain was 3.0 Ϯ 1.7 SDS. Thanks to the therapy, at the end of the 7-year treatment period, average height in the entire series was not significantly far from mean target height (TH) (¹0.7 Ϯ 1.3 vs ¹0.3 Ϯ 0.4 SDS) and average predicted height (PH) (¹0.2 Ϯ 1.4 SDS) was very close to TH. A stepwise regression analysis showed that both catch-up growth under therapy and PH at the end of the 7-year treatment period were positively influenced by birth weight (BW). Conclusions: a) Our 7-year prospective study on GHD infants treated with GH from less than 2 years of age confirmed the importance of early diagnosis and treatment of GHD in childhood. b) The influence of BW on growth response to GH therapy in GHD children persists over time, at least when treatment is begun from less than 2 years of age.

show abstract

Section: Discussionsupporting

confidence: 88%

Birth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age of 2 years

Waśniewska

Arrigo²,

Cisternino

et al. 2000

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In the past few years, there have been a few studies reporting long-term growth results after rGH therapy in early-treated GH-deficient patients [26, 27, 28, 29], but only one report on AH has been published [30]. In this report, we were able to confirm that early GH replacement therapy produced a normal and target-related AH in a group of patients with idiopathic GHD (fig.…”

Section: Ah Of Patients With Ghd Treated With Rgh Since the First Yeasupporting

confidence: 60%

Long-Term Results with Growth Hormone Therapy in Idiopathic Hypopituitarism

et al. 2000

View full text Add to dashboard Cite

More than 30 years after its introduction, growth hormone (GH) treatment is well established in children with GH deficiency. Nevertheless, the long-term results of this therapy, expressed as height, are generally considered unsatisfactory. We report on results obtained in a group of GH-deficient children who were treated with daily injections of recombinant GH within the first 5 years of life and who reached an adult height very close to their target height. The full catch-up growth to the target height demonstrated in these patients suggests that replacement therapy should be started early and continued until adulthood. Height at onset of puberty is an important variable which might significantly influence the adult height. The significant and prolonged influence of birth weight on growth response to GH therapy underlines the important role of fetal growth in planning early treatment of GH-deficient children.

show abstract

“…After infancy, the nutritional component of IGF-1-dependent growth is gradually replaced by GH stimulation on IGF-1 synthesis (20,27). During childhood, boys with CHH experienced relatively normal childhood growth.…”

Section: Discussionmentioning

confidence: 99%